Contract Manufacturing

Reliable and
Flexible Partner

Samsung Biologics offers advanced cGMP facilities providing safe and reliable clinical and commercial biologics. All processes are cGMP-compliant and meet the standards defined by regulatory authorities. Our dedication to quality and optimized services are visible in everything we do from clinical to commercial production.

Large Scale

As the world’s largest CDMO by production capacity, we can offer the large-scale commercial manufacturing of drug substance in multiple scales and capacity. The downstream suites are equipped with chromatography skids, columns, UF/DF skids, virus filtration skids, and Grade A bulk filling capacity, as well as product pool vessel capacities from 200 liters to 15,000 liters to handle a wide range of pool volumes.

Small Scale

Equipped with a wide range of bioreactor sizes as well as new manufacturing technology, we offer multiple cGMP manufacturing facilities to deliver the production volumes required by our clients at any given time. Our small-scale manufacturing facility has the same best-in-class characteristics and equipment as our large-scale plants, featuring stainless steel and single-use bioreactors at 1,000 liter scale, and one purification suite with pre- and post-viral segregation.

Multiples Scales, Multiple Capacities,
to fit various processes for any production volume

1K x2 Single-use , 1K x2 Stainless steel sCMO 4,000L 1k*2 Single-use, 1k*2 Stainless steel
Plant 130,000L
5K x6 Stainless steel plant1 30,000L 5k * 6 Stainless steel, plant2 150,000L 15k * 10 Stainless steel, plant3 180,000L 15k * 12 *1 Stainless steel
Plant 2150,000L
15K x10 Stainless steel
Plant 3180,000L
15K x12 1* Stainless steel Plant4 246,000L 15k *12 Stainless steel, 10k *6 Stainless steel(operation starting in October 2022), 2k *8 Stainless steel
Plant 4 2 **256,000L
15K x12 Stainless steel, 10K x6 Stainless steel (Operation starting in October 2022), 2K x8 Stainless steel
  • 1 * Plant 3 has Fed-batch with N-1 Perfusion Capability
    2 ** Scheduled to be fully GMP ready by the end of 2023
    3 *** Operation starting in October 2022
  • Learn about our Plant 4



Thank you for Subscribing to Our Newsletter

아래 다운로드 버튼을 클릭하시면 바로 다운로드 하실 수 있습니다.


Subscribe to Our Newsletter

파일 다운로드를 위해 뉴스레터 구독용 이메일 주소를 입력해주세요.
* 구독자라면 구독중인 이메일 주소를 입력해주세요.

뉴스레터 구독 서비스 유무 확인

Subscribe to Our Newsletter

뉴스레터 구독 서비스를 등록하시면 당사 뉴스룸에서 제공되는
삼성바이오로직스의 최신 소식과 관심 분야별 유용한 정보를 받아 보실 수 있습니다.

Subscribe to Our Newsletter
    • - 개인정보 수집 목적 : 이메일 발신서비스 제공
    • - 개인정보 수집 항목 : 이메일 주소, 회사명, 이름, 직급, 국가
    • - 이용 및 보관 기간 : 이메일 발신서비스 해지 시까지

    개인정보 수집에 동의하지 않을 시, 뉴스레터 서비스를 이용할 수 없습니다.

    삼성바이오로직스 개인정보 보호정책에 따라 개인정보는 안전하게 관리됩니다.



Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.

Copyright Samsung Biologics. All rights reserved